| Gene symbol | E2F1 | Synonyms | E2F-1, RBAP1, RBBP3, RBP3 | Type of gene | protein-coding |
| Chromosome | 20 | Map location | 20q11.22 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | E2F transcription factor 1 | ||||
| Gene symbol | SPAM1 | Synonyms | HEL-S-96n, HYA1, HYAL1, HYAL3, HYAL5, PH-20, PH20, SPAG15 | Type of gene | protein-coding |
| Chromosome | 7 | Map location | 7q31.32 | dbXrefs | |
| Description | sperm adhesion molecule 1 | ||||
| GTO ID | GTC3983 |
| Trial ID | NCT02045589 |
| Disease | Pancreatic Adenocarcinoma |
| Altered gene | E2F1|PH20 |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | DNA oncolytic virus |
| Treatment | VCN-01 |
| Co-treatment | Gemcitabine|Abraxane |
| Phase | Phase1 |
| Recruitment status | Completed |
| Title | A Phase I, Multicenter, Open-label, Dose Escalation Study of Intratumoral Injections of VCN-01 Oncolytic Adenovirus With Intravenous Gemcitabine and Abraxane® in Advanced Pancreatic Cancer |
| Year | 2014 |
| Country | Spain |
| Company sponsor | Theriva Biologics SL |
| Other ID(s) | P-VCNA-002|2012-005556-42 |
| Vector information | |||||||||||||
|
|||||||||||||
| Cohort 1 | |||||||||
|
|||||||||